Diagnostic Value of Lumbar Facet Joint Injection: A Prospective Triple Cross-Over Study by Schütz, Uwe et al.
Diagnostic Value of Lumbar Facet Joint Injection: A
Prospective Triple Cross-Over Study
Uwe Schu ¨tz
1*, Balkan Cakir
2, Karsten Dreinho ¨fer
3, Marcus Richter
4, Holger Koepp
4
1Department of Diagnostic and Interventional Radiology, University of Ulm, Ulm, Germany, 2Department of Orthopedics, University of Ulm, Ulm, Germany, 3Institute for
muskuloskeletal Rehabilitation, Prevention and Health Service Research at Charite ´ Universita ¨tsmedizin Berlin, CSSB and CMSC, Berlin, Germany, 4Spine Center, St. Josefs-
Hospital, Wiesbaden, Germany
Abstract
The diagnosis ‘‘lumbar facet syndrome’’ is common and often indicates severe lumbar spine surgery procedures. It is
doubtful whether a painful facet joint (FJ) can be identified by a single FJ block. The aim of this study was to clarify the
validity of a single and placebo controlled bilateral FJ blocks using local anesthetics. A prospective single blinded triple
cross-over study was performed. 60 patients (31 f, 29 m, mean age 53.2 yrs (22–73)) with chronic low back pain (mean pain
persistance 31 months, 6 months of conservative treatment without success) admitted to a local orthopaedic department
for surgical or conservative therapy of chronic LBP, were included in the study. Effect on pain reduction (10 point rating
scale) was measured. The 60 subjects were divided into six groups with three defined sequences of fluoroscopically guided
bilateral monosegmental lumbar FJ test injections in ‘‘oblique needle’’ technique: verum-(local anaesthetic-), placebo-
(sodium chloride-) and sham-injection. Carry-over and periodic effects were evaluated and a descriptive and statistical
analysis regarding the effectiveness, difference and equality of the FJ injections and the different responses was performed.
The results show a high rate of non-response, which documents the lack of reliable and valid predictors for a positive
response towards FJ blocks. There was a high rate of placebo reactions noted, including subjects who previously or later
reacted positively to verum injections. Equivalence was shown among verum vs. placebo and partly vs. sham also. With
regard to test validity criteria, a single intraarticular FJ block with local anesthetics is not useful to detect the pain-
responsible FJ and therefore is no valid and reliable diagostic tool to specify indication of lumbar spine surgery.
Comparative FJ blocks with local anesthetics and placebo-controls have to be interpretated carefully also, because they
solely give no proper diagnosis on FJ being main pain generator.
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Introduction
In 1911, Goldthwait [1] suggested lumbar facet joints (FJ) as a
source of low back pain (LBP). Ghormley [2] coined the term
‘‘facet joint syndrome’’ (FJS) in 1933 and was the first who
described the combination of symptoms caused by lumbar FJ
degeneration. In 1954, Hirsch et al. [3] described the possibility of
FJ pain provocation by injecting saline solution intraarticularly
and thus evoking ‘‘memory pain’’. Mooney and Robertson [4]
reported that experimentally caused pain can be relieved by
injecting local anesthetics (LA) into FJ, which was the basis for a
diagnostic and therapeutic procedure, the so-called facet joint
block (FJB). Today, lumbar FJS is widely used as a clinical
diagnosis even though there is is still discussion in the literature,
whether it is an actual disease or a symptom [5,6,7,8,9]. This
diagnosis is mostly made by exclusion of other causes of pain.
As the intervertebral discs are compressed in the upright
position, the facet joints are subject to compression under (hyper-)
extension of the spine. The amount of force was calculated at 16%
(3–25%) of the entire compression force of the lumbar spine
[10,11]. The strain of the lumbar FJ is highest in maximal
extension. The reduction of disc height also increases the load
[12,13,14], which leads to degeneration of the FJ [15,16].
Autonomous nerves in FJ have been proven to explain the role
of the FJ in LBP [17]. However, the role of nociceptors is still
discussed controversially [18,19,20,21]. A dual innervation of the
FJ (posterior branches from the same segment and the adjacent
cranial segment) was proven, which explains overlapping zones of
referred pain [22,23,24,25,26]. Main factors of degeneration are
age, height of the respective segment, especially in case of the
lower lumbar segments, and the FJ angle [27].
Schleifer et al. [28] developed a clinical score for grading the
discomfort caused by FJS, which included the parameter finger-
floor distance, lumbar spine rotation, Schober’s index and the
10 point visual analog scale (VAS). Helbig [8] suggested that LBP
decreasing with extension and rotation in combination with
degenerative FJ changes in x-ray had a high correlation with FJ
pain. Schwarzer et al. [29], however, dismissed the criteria
reported by Helbig [8]. Correlation between radiological imaging
techniques and clinical findings and the distinguishing between
symptomatic and asymptomatic individuals using conventional x-
ray, CT-and MRI scan or SPECT) is limited and unreliable
[30,31,32,33,34].
Because of unspecific and inconsistent clinical symptoms (local
and pseudoradicular pain) [5] and a low predictive value of
diagnostic imaging, interventional tests for detection of degener-
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diagnostic FJB by facet joint injection (FJI) using LA is therefore
to numb a FJ and thus to identify it as the origion of pain. Residual
pain after FJB is not attributed to the injected joint [34].
In literature [38,39] the following responder or predictor
criteria were mentioned to indicate a positive response to a FJB:
advanced age, history of LBP, no leg pain, Valsalva test negative,
no muscle spasms, normal gait, and increasing pain following
flexion. None of these specific studies were able to produce a
significant predictive value or parameter (anamnestic, clinical,
functional) [40,41].
The prevalence of a disease defines the importance of correct
test results. Therefore, diagnostic tests in a population with high
prevalence of a specific pathology are more important than in
populations with a lesser frequency of the same pathology. Some
investigators, with limited evidence and no gold standard, suggest
that the prevalence of FJ involvement in LBP seems to be 15–40%,
with LBP caused solely by the FJ as low as 7% [38,42,43].
The FJI as diagnostic tool for FJS is a widely accepted
instrument in spine surgery for preoperative diagnostic. The
results are often used in decision making for FJ denervation,
segmental dynamic or rigid stabilization [44].
The property clinicians expect most from a diagnostic test is a
good predictive value, which is a function of the specifity,
sensitivity, and validity of the test applied, as well as safety (low
rate of complications) and reliability (reproducibility). It is
considered impossible to accurately determine specificity and
sensitivity in spine related issues [35]. For diagnostic tests such as
FJI with the aim of the test being presence or absence of pain,
there is no reliable gold standard.
There are numerous reports on diagnostic lumbar FJB
[5,25,25,40,41,42,45,46,47,48,49,50,51,52]. However, the aplied
techniques vary widely and therefore their comparability is
limited. FJI without radiologic control of needle positioning lacks
precision and shows a higher risk of complications [53]. Jerosch
et al. [52] were able to show in a human cadaver study that the
median inaccurateness is 2.3 mm for injection under x-ray control.
The highest specificity was reached with MRI or CT guidance
[35], however, effort and costs lead to a preference of fluorescent
imaging [50]. The risk of FJB is generally low, although there are
case reports on infections [45,54,55,56,57,58,59,60].
Purpose
Randomized studies have been published in which either
placebo or verum was injected [41]. However, due to the
complexity of the symptoms, it is preferred that both agents are
injected in the same patient. A ‘‘cross-over design‘‘ regarding these
necessities has not been published to date. The present study
examined whether a lumbar FJI is suitable to identify FJ’s as pain
originating structures or whether optimization of the preclinical
testing is necessary to enhance the probability of the prevalence.
The problem of placebo effects is also addressed.
Materials and Methods
Design
A prospective, clinical, randomized, closed, single-blinded,
triple cross-over study with six parallel groups was performed.
Verum agent and placebo were applied as intraarticular FJI in all
patients. According to study protocol, each patient received three
bilateral injections: verum (V: 1.5 ml 1% Mepivacaine), placebo
(P: 1.5 ml 0.9% isotonic sodium chloride solution) and sham
injection (S: only extraarticular positioning of the needle without
volume application, in order to avoid irritation of the joint capsule)
after a period between 8 and 12 hours (wash out period). If the
patient was still reporting a benefit from the previous injection, the
following injection was also performed, however, the current pain
level was taken as base for the following injection. For the
injections, gauge 22–23 needles with a length of 5–15 cm (3.5–
5 in.) were used. In order to avoid additional irritation, local
anesthesia of the skin or contrast medium application were
avoided.
The order of injections (=sequence) was randomized according
to a protocol created by the local Department of Biometrics and
Medical Documentation leading to 6 evenly split sequence-groups
(table 1).
Patient sample
60 consecutive patients admitted to the local orthopaedic
department for surgical or conservative therapy of chronic LBP
were included in the study. These patients had undergone
adequate conservative outpatient treatment for chronic LBP for
at least 6 months without success. The mean age (31 f, 29 m) was
53.2 years (22–73).
Exclusion criteria were age under 18 and over 75 years,
intermittent LBP triggered solely by stress, pain during the night or
mainly ischialgia with positive Valsalva or Lase `gue test. Patients
with radicular pain referable to the same segments of FJ
degeneration were not accepted. Patients with maximum local
pain in the thoracolumbar region, sacroiliac pain or with a history
of major surgical procedures of the lumbar spine (like dorsal
instrumentation, intervertebral fusion, dorsal spondylodesis, disc
prosthesis), osteonecrosis, tumor or severe anatomical deformities,
local or systemic infection, tendency towards bleeding, severe
osteoporosis, metabolic bone disease, kidney failure, obesity (Broca
index .30), pregnancy, allergy to any of the agents applied, or
poor compliance were also excluded from the study.
Patients fulfilling these criteria had their medical history taken
and underwent a physical examination including evaluation of
radiological imaging (plain film radiographs of the lumbar spine in
2 views, CT and MRI scans) according to the criteria introduced
by Helbig [8], Fairbank [61] and Schleifer et al. [28]. All patients
had standard x-rays of the lumbar spine in 2 planes (a.p. and
lateral), 91.7% of the patients had MRI of the lumbar spine and
8.3% a CT scan, also. For radiological findings, see figure 1.
Radiological entities diagnosed on radiographic images of the LS
are multifold and most patients have had more than one. All
patients showed degenerative facet joint arthritis in the injected
segment, 56.7% in 2 segments and 16.7% in more than 2
segments. Pain pattern showed local lumbar back bain and/or
pseudoradicular pain in the buttuck or groin. In 4 patients (6.6%)
a selective nucleotomy (minimal invasive surgery) was performed
more than 18 months ago. In 3 of these cases, the operated
Table 1. Sequences (groups of possible injection series).
1
st injection
A
2
nd injection
B
3
rd injection
C
1. group (n=10): SPV sham placebo verum
2. group (n=10): SVP sham verum placebo
3. group (n=10): PSV placebo sham verum
4. group (n=10): PVS placebo verum sham
5. group (n=10): VPS verum placebo sham
6. group (n=10): VSP verum sham placebo
doi:10.1371/journal.pone.0027991.t001
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postnucleotomy syndrome with intraspinal scar tissue or instability
was not present at time of investigation. On contrast enhanced
MR images of LS peridural adhesions or neuronal alteration due
to scars in the spinal or neuroforaminal regions were not
detectable and they did not suffer from radicular pain in the last
12 months. They only suffered from focal (lumbar, lumbosacral) or
pseudoradicular (gluteal) pain.
If a degenerative FJS was present, the patients were informed
about the content and course of the study and written informed
consent was obtained with approval of the local ethics committee
(University of Ulm, Ethikkommission, Helmholtzstr.20, 89081
Ulm, Germany, No.: 10/04-UBB/se.) and in accordance to the
Declaration of Helsinki. The patients were admitted to the study
according to the randomization plan when the current pain was
adequate (VAS.4) and no analgesics were taken 24 hours prior to
the first scheduled FJI.
All patients had local lumbar back pain, 44 patients (73.3%) had
pseudoradicular pain additionally. Another 11 (16.7%) patients
had intermitted radicular pain, which could be referred to spinal
segments above the indentified segments of FJ degeneration (all
L5/S1 in this subgroup). Pain had been present for an average of
31 months, with a range from 6 months to .10 years. In only 2
cases (3.3%) the level L3/4 was injected, otherwise FJI was done in
segments L4/5 (46.7%) or L5/S1 (50%).
Injection technique
In order to optimize fluoroscopy of lumbar FJ, we used the
‘‘oblique needle technique‘‘ (figure 2): the patient was placed in an
oblique prone position on the x-ray table, under consideration of
the particular lumbar facet joint anatomy [57,62]. The optimal
obliqueness for the upper lumbar FJ is 30u, for the lower FJ
approximately 60u [48,63]. This ensures an orthograde projection
of the lateral portion of the FJ. Several authors [44,48] have
identified this needle position to be best in order to avoid
iatrogenic cartilage damage.
For the exact diagnosis of pain syndromes relating to FJ, it is
considered as a crucial factor, that the injected agent is not be
allowed to diffuse into adjacent structures. Therefore, the joint
capacity must not be exceeded and the tip of the needle has to be
positioned intraarticularly [46]. The volume of the joint capsule
has been determined to be 1–2 ml [64,65]. Excess of this volume
will lead to a rupture of the joint capsule and extravasatation
[48,63].
In 60% of cases, the injection sequence was done within 2 days,
and 30% within 3 days. In 6 subjects (10%), the testing period
included a weekend which led to an extension of the testing period
to 4 days. During the study, no patient withdrew from the testing.
Statistical analysis
In this triple cross-over design, the interesting factor was the
effect of the injection. The subjects were blinded toward the
applied injection sequence. Target value was the pain level and the
change of pain intensity after FJI. The pain level was recorded
using a 10-point visual analogue scale (VAS: 0–10) before the
injection (time t0) and at definite time t1 (30 min), t2 (60 min), t3
(2–3 h) and t4 (6–8 h) after the injection. If degenerative FJS were
present in 2 or 3 segments, the segment which was clinically or
radiologically most likely affected was chosen. If a clear
identification was not possible, the statistically most likely affected
segment L4/5 was tested [34]. The latter occurred in only 1 case,
on all other 43 cases with more than 1 segment of FJ arthrosis
(figure 1) a segment with more severe degenerative condition could
be identified on radiological images.
Evaluation included description of the collective, dropouts and
comparison of sequences and descriptive statistical evaluation. To
Figure 1. Radiological findings (MRI, CT, X-ray).
doi:10.1371/journal.pone.0027991.g001
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data results were evaluated using a linear mixed model. For time
t1–t4 a special model was calculated (variance-component-model).
Target value was the difference of the score value before the
treatment (t0) minus the score value after an injection, separate for
t1, t2, t3 and t4. Cause variables were the sequence of injections
and pain level before injection. Disturbance variable was the time
between injections.
The test injection was considered positive if the difference of the
pain scores 2 pts (VAS) in minimum. In case of pain difference
below 2 pts or an increase of pain compared to the pain level
before FJI the test injection was regarded as negative. In other
words; a responder reacts to an injection (V, P or S) with a relevant
reduction of pain of at least 2 pts (D$2), a pain relief of less than
2 pts after injection (D,2) is defined as non-response.
With regard to the cross-over design, we checked for the presence
of a sequence (periodic) or carry-over effect. In this model, the
subject was considered incidental and, therefore, the combined
structure of the data was taken into consideration. All calculated
models were viewed as an explorative data analysis [41].
With regard to the carry-over effect, the tests for difference and
equivalence were based on the following hypothesis: the
physiological effect to the verum is not influenced by previous
injections (H0). With regard to the periodic effect the following
hypothesis was constructed: the physiological effect to the verum is
not influenced by the time of injection (H0).
For implementation of the testing on equivalence [41] of
different injections, the following hypotheses (H0) were construct-
ed: the 3 injections are not equivalent, therefore at least one
comparison of effects of two injections would result in a difference
more or less than D=2.
In order to enable comparison regarding the equivalence of
interventions, the differences of the estimated median values (verum
vs. placebo, verum vs. sham, placebo vs. sham) were calculated with
the 90% confidence intervals. If all 3 confidence intervals were
within the clinical relevant equivalence interval (D#+/21 equiv-
alence of the 3 different interventions (V,P,S) with a significance of
p=0.05 [41] is proven. If H0 is correct, this means that the
diagnostic FJI with verum is a sufficiently specific method for
differential diagnostic testing of a degenerative lumbar FJS.
The results were descriptively analyzed and evaluated using the
following differentiation (table 2): A total non-responder does react
to any injection with a pain relief less than 2 pts. (D,2). A true
verum-responder is given, when reaction to verum is at least 2 pts
better than to placebo (DV-DP$2) and when reaction to sham
injection is not positive (DS#0). A false positive reaction of a
verum responder is given, when reaction to verum is less than
2 pts better than to placebo (DP-DV$21) or when reaction is
positive to sham injection (DS.0). Placebo effect or sham injection
gives better pain relief than verum, when difference is positive
compared to verum (DP-DV$1, DS-DV$1).
Tests on difference regarding the change of pain level (10 pts-
VAS) between the 3 injection forms (V,P,S) at the different times
after FJI and between the 3 severity groups of FJS (classification of
Helbig [8] and Schleifer [28], table 3) were done, using signed-rank
tests for dependent ordinal scaled samples: the Friedmann test for
test on difference between all 3 types of injection (V,P,S), the
Wilcoxon-Test forpairedtest ondifference(V vs.P,V vs.S, P vs.S).
For all tests the level of significance was set on p=0.5.
Results
Carry over and periodic effect
At no time after injection (t1–t4) a carry over effect could be
demonstrated which means, that no injection type had any
influence on the subsequent injection (Table 3, Fig. 3) At time t2
there was a significant periodic effect (p,0.042), while at all other
times after injection this effect was absent (table 3, figure 4).
Pain relief
The distribution of the pain reduction caused by the injections
in relation to the pain level before the injection is shown in figure 5.
Thirty to 60 minutes after veum-injection the mean pain
reduction was 1.4 pts, later below 1 point. With a mean pain
Figure 2. Oblique needle technique of fluoroscopically guided lumbar fact joint injection.
doi:10.1371/journal.pone.0027991.g002
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was nearly on the same level. During the entire time period up to
8 hours after injection, the mean pain reduction after shame-
injection was lower than after verum or placebo; at 30/60 minutes
approximately 0.6–0.7 pts. Later, the mean difference between
shame and verum- or placebo-injection decreases considerably.
Responder rates
Responder rates regarding verum, placebo und sham-FJI are
depicted in Fig. 6: Among the entire sample at 30 and 60 minutes
after FJI, 33% respectively 28.3% had a total negative response to
any diagnostic FJI (total non-responder). At these times after
injection, 67.5% resp. 71% of the responders have been verum-
responders, however, in 2 out of 3 cases the placebo or sham
values were better (‘‘false positive’’). At t1, t2 and t3, approxi-
mately 50% of responders were placebo responders and 25–30%
were sham responders, indicating that the placebo effect in the
majority of the patients (.80%) led to more pain relief than the
verum. While at t1 the sham responder rate was 30% (42.5% of all
responders), at t2 the rate was 20% (30% of responders). After 2–
3 hours the non-responder rate was nearly 50%. Only 2 out of 3
subjacts at this point were verum responders. In cases with equal
reaction to placebo- and sham-injection, the pain reduction was
almost always equal or better than to verum. False negative
responses were not observed which means that there was no
increase in pain level following verum injection and pain reduction
following placebo- and/or sham-injection.
Test on equivalence
The estimated model based mean values of the target value with
regard to the different injection types are depicted in figure 7,
showing similar values of measured means of the sample collective.
The tests on equivalence showed a significant result for the
equivalence of verum vs. placebo FJI at each time after injection
(t1–t4), because all 90% confidence intervals of the estimated
means of the target value were within the limits for a relevant
change of pain level (D.1). This is shown in figure 8 by the
difference of the estimated means. For sham injection the test on
equivanlence vs. verum or placebo was partly significant at time 2
and 4 after FJI. Therefore, the test of difference in pain relief
indicates some significant difference for verum or placebo injection
vs. sham injection at the same times after FJI (table 3).
Tests on difference
There is no significant difference of pain reduction between
verum- and placebo-injection at any time after FJI (table 4).
Between sham-injection and verum- resp. placebo-injection there
is significant difference only 60 minutes after FJI (table 4). Figure 9
Table 2. Definitions of responder criterias.
total non responder true verum responder
‘‘false positive’’
verum responder
placebo responder
better than verum
sham responder better
than verum
DV,2
and
DP,2
and
DS,2
DP+2#DV$2
and
DS#0
DP+2.DV$2
or
DS.0
DV21#DP$2 DV21#DS$2
doi:10.1371/journal.pone.0027991.t002
Table 3. Severity of facet joint syndromes.
Scores:
Helbig et al. [8]
(total: 100 pts.) No. in sample [n]
Schleifer et al. [28]
(total 15 pts.) No. in sample [n]
Stage 1 $60 pts. 37 5–7 pts. 33
Stage 2 $40 pts. 27 9–11 pts. 23
Stage 3 ,40 pts. 6 12–15 pts. 6
subgrouping Pts. subgrouping Pts.
Groin or
thigh pain
30 44 FGD (finger
ground distance)
1: .20 cm
2:10–20 cm
3: 0–10 cm
21
31
8
Paraspinal
tenderness
20 15 Schober’s index 1: 0–2 cm
2: 2–5 cm
3: .5c m
23
24
13
Pain in
extension-rotation
30 36 Rotation LS 1: fixed
2: limited
3: .20u
14
35
11
Typical radiographic
changes
20 60 Lumbago VAS 1: .5
2: 3–5
3: 0–2
45
13
2
Pain below
the knee
210 11 Pseudoradicular VAS 1: .5
2: 3–5
3: 0–2
29
11
4
doi:10.1371/journal.pone.0027991.t003
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time 1,2 and 3 after FJI. As the wide spread indicates, the tests on
difference between the severity for stage 1,2 and 3 (classification of
Helbig [8] and Schleifer [28]) regarding significance of pain relief
are not significant at any time after FJI and for any type of FJI (not
for V, not for P and not for S). Tests on difference of patients with
stage 3 severity were not possible due the low number in this
sample (n=6, table 3).
Prior nucleotomy
In 3 of the 4 patients with prior nucleotomy a positive pain relief
is seen after verum and placebo at time 1 and 2 after injection, 1
patient showed no response to all injections. In 2 patients pain
relief is measured after sham injection at time 1 and 2 also. Due to
the small number of 4 patients statistical analysis on difference to
patients without prior operative intervention was not possible.
Discussion
Equivalence of verum and placebo
Early studies of FJI with steroids and anesthetic agents for
diagnosis and therapy were encouraging; short-term pain relief
from 59% up to 94% and long-term pain relief from 27% to 65%
after a single injection were reported [23,47,66]. This led to the
conclusion that FJB is simple, safe, and cost-effective, and the
technique should be used in the management of LBP. However,
Figure 3. Carry over effect in sequences.
doi:10.1371/journal.pone.0027991.g003
Figure 4. Period effect in sequences.
doi:10.1371/journal.pone.0027991.g004
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doi:10.1371/journal.pone.0027991.g005
Figure 6. Specific responder rates.
doi:10.1371/journal.pone.0027991.g006
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data (the patient is regarded as coincidental in the model). Random sample.
doi:10.1371/journal.pone.0027991.g007
Figure 8. Test on equivalence of injections.
doi:10.1371/journal.pone.0027991.g008
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that even without a placebo effect, one does not have to block the
actual painful site of pathology directly to have subjective pain
relief [67,68]. In a prospective, controlled study of FJI, Lilius et al.
[69] tested 109 patients with chronic LPB. The patients randomly
received one of three types of injections: corticosteroid and local
anesthetic into two FJ, the same mixture periarticular of two FJ, or
physiologic saline into two FJ. 64% of the patients reported initial
relief of pain, and 36% had benefits persisting up to 3 months. The
benefit was independent of the mode of treatment given; results in
patients injected with saline were as good as results in those
injected with local anesthetic and steroids. It was therefore
assumed that the mode of injection did not affect the outcome,
but the outcome correlated closely with the results of the
psychosocial tests.
We were able to confirm these results with a controlled triple
cross-over design. At time point 2 the periodic effect and thus the
test for difference became significant (table 4). This result,
however, does not contradict the significant results of the tests
for equivalence between verum and placebo, because the
estimated means for therapy, carry-over effect and periodic effect
were adjusted [65].
Lack of clinical predictors
The lack of reliable clinical predictors with regard to FJ pain on
the lumbar spine was confirmed by our relatively high rate of non-
responders of 33%. The rate for positive tests (true verum
responder) was only 16.5% (figure 6). Moran et al., 1986 [51] got
the same results with their setting: 54 patients, 143 FJI,
prospective, strictly intracapsular, test positivity at pain provoca-
tion (0.5–1 ml anionic contrast medium) and relief (,1.5 ml
bupivacaine). Unfortunately, due to lack of a control group and
only unilateral injections, their results are only interpretable in
part. Raymond and Dumas, 1984 [44], used a strictly intracap-
sular injection technique with 16% positive results, also. Our
results for positive NaCl reaction were also confirmed in the
literature: in one study 30% of individuals receiving subcutaneous
or saline injections rather than lumbar facet joint blocks
experienced relief of their facet joint pain [43].
In our sample, classification of clinical and radiological findings
in FJS severity scores like suggested by [8] and Schleifer [28]
indicated no significant difference in pain relief, not for verum and
not for placebo FJI. Like Schwarzer et al. [29], we have to
conclude, that these scores are really doubtful regarding validity
and therefore, they are not notacceptable for application in
diagnostical or therapeutical procedures in clinical practice. North
et al., 1996 [66] tested three different nerve blocks by blinded
patients in a randomized sequence compared to a control lumbar
subcutaneous injection of an identical volume of 3 ml of 0.5%
bupivacaine. There were no associations between the results of
blocks and clinical findings (history, physical examination,
diagnostic imaging) in these patients, chosen for their homoge-
neous clinical presentation and absence of functional signs. Their
results confirmed the hypothesis that false positive results are
common and specificity is low. This lack of specificity may,
however, be advantageous in therapeutic applications, but this is
not proven by cross over studies like our till now.
Extravasation
The large volumes injected in the early investigations almost
certainly resulted in capsular rupture with extravasations of local
anesthetic and steroids. In many reports the volume of the
injected LA exceeded the capacity of the FJ by far, thus
increasing the probability that the effect of FJB was due to other,
extraarticular mechanisms [51]. Raymond and Dumas [44], in a
study of 25 patients, prevented extravasations by restricting the
total volume of fluid injected to 1 ml. Overall relief of pain in
their series differed dramatically from that in other series—16%
temporary relief and no long-term relief. Moran et al. [51]
restricted injection volume; they achieved only a 13% success
rate. This extravasate was found in the epidural space rather than
in the paravertebral tissue [51,65], thus leading to epidural and/
or segmental nerve root blocks [52]. The positive effects of
epidural blocks are well documented [52] and may result in a
reduction of pain which is considered a positive effect [24]. A
differentiation of the effect as wanted for diagnostic test blocks
was not possible.
Lynch and Taylor [70], however, contradict the work by
Raymond and Dumas [44] and Moran et al. [51]. They
administered two injections of 1 ml of fluid containing corticoste-
roids in 50 patients. Patients were classified as having both, one, or
neither of the injections put into the capsule. The results showed
that intraarticular injections were more effective than extraarti-
cular injections for long-term pain relief. There were no control
groups.
We performed intraarticular test injections with local anesthetics
and contrast medium (total volume 1.5 ml) in 8 patients which
were not part of the study group applying the same technique and
found extravasations in half of the patients (4) even though the
needle was placed correctly (figure 2).
Prior nucleotomy
LFJ syndrome is a known possible consequence after nucleot-
omy, due to mechanical pathological load resulting from loss of
intervertebral distance [28]. Like the patients without operation at
LS in their history, the patients with prior nucleotomy (minimal
invasive intervention) show positive pain reduction in 75% of cases
also. One of these patients is a total non-responder, like 30–50% of
non operated patients are. Compared to prior non-operated
subjects, descriptive analysis shows no difference in response
reaction on injections, although a statistical analysis on significance
was not possible due to small number of this group.
False positive reactions
According to our results a single intraarticular FJI does not
confirm the diagnosis of a FJS. We found a low specificity (high
rate of 66% false-positive verum responders) and a low sensitivity
(high rate of positive sham reactions in patients with negative
verum reaction). Other investigators suggest the reproducibility of
the single (uncontrolled) injection is not high, and the specificity
may be about 65%. Schwarzer et al. [71] clearly showed in a
Table 4. Tests on difference.
effect t1 t2 t3 t4
carry-over effect 0.788 0.535 0.566 0.138
period effect 0.073 0.042* 0.598 0.813
pain relief
V vs. P vs. S 0.087 0.026* 0.060 0.023*
V vs. P 0.132 0.11 0.108 0.098
V vs. S 0.087 0.034* 0.089 0.065
P vs. S 0.077 0.045* 0.097 0.021*
*p=0.05.
t1: 30 min after FJI, t2 60 min after FJI, t3: 2–3 h after FJI, t4: 6–8 h after FJI.
doi:10.1371/journal.pone.0027991.t004
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rate of 38%. However, the anesthetic response to a single
uncontrolled FJB is as high as 50%. The argument has therefore
been made that a single uncontrolled facet block will inherently
have an unacceptably high false-positive rate and a low positive
predictive value [71].
Jackson et al. [38] performed an elaborate study on 390 patients
in which they used intraarticular injections of only 1 ml of 0.5%
bupivacaine and 2 mg (0.5 ml) of triamcinolone. The investigators
evaluated 127 variables and found that more pain relief was
associated with older age, history of LBP, normal gait, maximum
pain on extension after forward flexion in the standing position,
Figure 9. Relative pain relief after FJI in dependence to prior FJS severity.
doi:10.1371/journal.pone.0027991.g009
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the valsalva maneuver was performed. The authors concluded,
however, that the FJ were not commonly the single or primary
cause of LBP in most patients. Therefore, it can be assumed that
patients with positive test result do not only have pain originating
from FJ, but from co-factors which cannot be identified due to the
lack of clinical predictors.
Placebo
Figure 6 shows that 3 and 6–8 hours after FJI a similar amount
of patients were true verum responders as 30 and 60 minutes after
FJI. Since the local analgesia following mepivacaine injection is
reported to content 3–4 hours [72], a positive effect after 5 hours
is not only due to verum reaction but also other factors. Thus
placebo reactions are to be expected in verum responders from our
results as well.
In cases of (sub-) chronic LBP we can assume that a greater rate
of patients already suffer from somatic pain disorders, which
would explain a certain influence of placebo reactions on verum
injections caused by psychosomatic factors. Temporary ‘‘diagnos-
tic’’ nerve blocks may be nonspecific in localizing pathology which
generates or maintains an ongoing chronic pain problem [66].
Sham injections
In literature, periarticular sicca sham injections in lumbar FJ is
not discussed or compared to volume injections till now. At time 2
and 4 after FJI the sham injection partly shows relevant difference
to verum and/or placebo. Relevant relief of pain level was set as
D.1, This is very low; with a level of significance of D.2, the
injection types (V,P,S) would have been equal at any time after
FJI. Equality of extraarticular sham injection without volume to
the intraarticular volume injection was significant in most but not
all cases in our sample. But tendency of lower placebo effects of
sham injection compared to placebo injection could be shown.
Further inverstigations should confirm the hypothesis, that
intraarticular volume application in lumbar FJ influences pain
perception resp. placebo effects more than perifocal simple sham
therapeutic procedure.
Gold standard
It is essential to have a gold standard with which to compare the
accuracy of a given diagnostic test. Numerous studies have
described the technique and clinical results of diagnostic blocks for
chronic LBP (Table 4). Saal describes as the gold standard of
diagnostic FJB the highly controlled (CT, MRI) FJB at the median
nerve branch (MBB) [35]. Dreyfuss concludes from his meta
analysis that FJB via MBB or LA-FJI has the same specificity
[34,48]. Reproducibility of the test is not high: the specificity is
only 65% [72,73]. However, the specificity of diagnostic MBB is
also not high, with false-positive rates ranging from 25% to 38%
[71,74,75]. Standard blockade injections of the medial branches
seem to anesthetize the joint and also the muscles, ligaments and
periosteum they innervate [74].
Despite these known neurophysiologic limitations, the known
problems with validity and specificity, the FJI are commonly used
for the diagnosis of suspected pathology in the FJ. But due to the
discussed reasons, the single local FJB via LA as diagnostic tool for
FJS has to be abandoned. Therefore, the assessment of the severity
of the clinical relevant degenerative FJS and of the success of the
therapy lies in the optimization of the specificity of the diagnostic
tool. Leclaire et al. [76] approximately indicated in their discussion
that diagnosing FJ mediated pain is more effectively done via
comparative anesthetic (and saline placebo) blocks. To obtain a
safe result, 3 blocks would have to be performed: one with LA and
2 with NaCl (placebo) or LA in a blinded setting [77]. The current
standard of diagnosing FJ-mediated pain via comparative local
anesthetic blocks with placebo-controls is exacting. And although
our results show, that interpretation of these testing has its limits
and that the results are not valid, it should be a standard that we
must uphold for the sake of our patients because it’s the only
standard we have till now. There is no completely reliable gold
standard with which to compare a diagnostic test (or injection)
when the absence of pain is the end point [35]. A true comparison
is not possible. The test results have to be interpretated in the
context of all clinical and radiological findings and the somatic and
psychological patient history. They are not able to give diagnosis
of the FJ being a major pain generator on their own.
Conclusions
With regard to test validity criteria, a single intraarticular facet
block with local anesthetics is not useful to prove a FJS and has to
be abandoned from preoperative testing and indication finding.
Although several studies have been performed in the last decades,
evaluation of FJI remains difficult due to lack of reliable clinical
and radiological predictors. Comparative FJ blocks with local
anesthetics and placebo-controls give no proper diagnosis on FJ
being main pain generator. But they they are the only standard we
have till now.
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